Spencer Langevin, MD
Retina Specialist · Slingerlands, NYNPI 1467859314
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for retina specialist clinicians in NY, where the typical reported total is $2,298.
Across 42 payments — averaging $59.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$457
- AbbVie$346
- Alcon$344
- Sight Sciences, Inc.$275
- Bausch & Lomb Americas Inc.$269
- Genentech USA, Inc.$266
- plus $528 from 7 others
What the payments were for
- Food & beverage$2,485100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 3 | $457 |
| AbbVie | 5 | $346 |
| Alcon | 5 | $344 |
| Sight Sciences, Inc. | 2 | $275 |
| Bausch & Lomb Americas Inc. | 3 | $269 |
| Genentech USA, Inc. | 6 | $266 |
| Regeneron Healthcare Solutions, Inc. | 5 | $130 |
| Oyster Point Pharma, Inc. | 1 | $115 |
| Aerie Pharmaceuticals, Inc. | 4 | $85 |
| Apellis Pharmaceuticals, Inc. | 3 | $70 |
| Astellas Pharma US Inc | 2 | $50 |
| ANI Pharmaceuticals, Inc. | 2 | $43 |
| Mallinckrodt Hospital Products Inc. | 1 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$364
- OMNI(R) SURGICAL SYSTEM (US)$275
- Prokera$172
- AmnioGraft$172
- VABYSMO$150
- XEN GLAUCOMA TREATMENT SYSTEM$147
- Rocklatan$125
- SION SURGICAL INSTRUMENT$125
- OZURDEX$125
- TYRVAYA$115
- Clareon PanOptix Pro$105
How this compares
$2,485 in reported general payments places this provider in the 50th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 24 | $71,807 |
| RestasisCyclosporine | 19 | $20,079 |
| Brimonidine Tartrate | 98 | $16,238 |
| LumiganBimatoprost | 20 | $11,261 |
| RhopressaNetarsudil Mesylate | 22 | $11,189 |
| CombiganBrimonidine Tartrate/Timolol | 32 | $9,065 |
| Prednisolone Acetate | 140 | $7,817 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 30 | $6,996 |
| Alphagan PBrimonidine Tartrate | 16 | $5,418 |
| Bromfenac Sodium | 26 | $4,421 |
| Latanoprost | 351 | $4,213 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 25 | $2,836 |
| Ketorolac Tromethamine | 81 | $2,360 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 115 | $1,908 |
| Azelastine Hcl | 59 | $1,339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Eylea | $130 | $71,80724 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $346 | $45,82387 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $85 | $11,18922 claims |
| AlconSimbrinza | $344 | $6,99630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 99 retina specialist providers in New York.
Other retina specialist in Slingerlands
- Paul HahnNanuet$238K
- Deepika MalikWoodbury$221K
- Szilard KissNew York$195K
- Ferhina AliValhalla$176K
- Donald D'amicoNew York$109K
- Matthew WitmerRochester$62K
- Avnish DeobhaktaBrooklyn$46K
- Edward HallRochester$38K
- Philip NilesWilliamsville$30K
- Mark BreazzanoLiverpool$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.